Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

VRTX · Q3 2025 Earnings

Vertex Pharmaceuticals

Reported November 3, 2025

30-second summary

Vertex posted Q3 revenue of $3.08B (+11% YoY) with non-GAAP EPS of $4.80 and a 45.0% non-GAAP operating margin, and tightened FY2025 revenue guidance to $11.9–12.0B by lifting the low end $50M. The more important guidance moves were elsewhere: combined non-GAAP R&D/AIPR&D/SG&A was raised to $5.0–5.1B from $4.9–5.0B — a ~$100M opex step-up explicitly tied to Journavx commercial acceleration and povetacicept program investment (the GAAP equivalent moved from $5.55–5.7B to $5.65–5.8B) — offset by a non-GAAP tax rate cut to 17–18% from 20.5–21.5%. The pain franchise crossed 300,000 YTD prescriptions and management is now explicitly framing Journavx as "another multi-billion dollar franchise."

Headline numbers

EPS

Q3 FY2025

$4.80

Revenue

Q3 FY2025

$3.08B

+11.0% YoY

Gross margin

Q3 FY2025

86.5%

Operating margin

Q3 FY2025

38.6%

Key financials

Q3 FY2025

Metric	Q3 FY2025	YoY	Q2 FY2025	QoQ
Revenue	$3.08B	+11.0%	$2.96B	+4.1%
EPS	$4.80	—	$4.52	+6.2%
Gross margin	86.5%	—	86.2%	+27bps
Operating margin	38.6%	—	38.8%	-23bps

Guidance

Revenue guidance slightly raised and operating expense guidance increased materially, offset by a significant tax rate cut.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Revenue	FY2025	$11.85 to $12.0 billion	$11.9 to $12.0 billion	+$50M at low end	Raised
Combined non-GAAP R&D, AIPR&D and SG&A expenses	FY2025	$4.9 to $5.0 billion	$5.0 to $5.1 billion (SG&A); $5.65 to $5.8 billion (combined)	+$100M to +$200M combined	Raised
Non-GAAP effective tax rate	FY2025	20.5% to 21.5%	17% to 18%	-350 to -350 bps	Lowered

Segment KPIs

Q3 FY2025

Segment	Q3 FY2025	YoY
TRIKAFTA/KAFTRIO	$2.65B	+2.6%

Other KPIs

Q3 FY2025

Segment	Q3 FY2025	YoY
United States	$1.98B	+15.0%
Outside United States	$1.1B	+4.0%
CF patients on Vertex medicines (eligible patient population coverage)	~95% of core markets	—
CASGEVY cumulative patients with cell collection	165 (SCD/TDT combined)	—
CASGEVY cumulative patients infused	39 (SCD/TDT combined)	—
JOURNAVX prescriptions written and filled (YTD)	300,000+	—
JOURNAVX covered lives	170+ million (>50% of U.S.)	—
JOURNAVX healthcare systems with formulary inclusion	90 of 150 targeted large systems; 750+ of 2,000 targeted hospitals	—
Povetacicept Phase 3 IgAN study	Full enrollment completed	—
Non-GAAP operating margin	45.0%	—

Management tone

Q4 2024 launch sequencing → Q1 2025 multi-franchise execution → Q2 2025 strategic discipline (killing VX993 mono, narrowing PNP to DPN, cutting povetacicept indication list) → Q3 2025 capacity expansion (initiating second renal indication for POVI before lead-program data, building commercialization team early).

Vertex has stopped sequencing launches and started running them in parallel. Last quarter's tone was about narrowing focus — killing assets, cutting indication lists, accepting a DPN-first regulatory path. This quarter it inverts: management initiated the pivotal study for POVI in primary membranous nephropathy before the lead IgAN data reads, and disclosed that "we have begun the build-out of our commercialization team" for renal. From the press release: "we are pleased to have initiated the pivotal study for the second potential renal indication for POVI in primary membranous nephropathy." Companies don't run a second pivotal trial and build commercial infrastructure for a franchise that hasn't shown lead-program Phase 3 data unless internal conviction is unusually high.

Pain has been re-framed from launch execution to franchise scale. A quarter ago Journavx was discussed in terms of covered lives and formulary milestones. This quarter management used the phrase "we're in the early days of creating another multi-billion dollar franchise for Vertex" — the same vocabulary used to describe the CF business. The 300,000+ YTD prescriptions and 170M covered lives (>50% of the U.S.) put substance behind that framing, but the $20M revenue number suggests gross-to-net is still doing significant damage to reported numbers.

POVI moved from "promising Phase 2" to a near-approval asset in two quarters. The clinical narrative shifted hard: "the FDA has granted POVI breakthrough therapy designation and rolling review for our BLA," combined with "we will begin our submission for potential accelerated approval before the end of this year." The 600-patient Phase 3 enrolled in 15 months — characterized as "the fastest of any contemporary Phase III study in IgAN" — is now the company's go-to evidence for the unmet need claim.

The opex guide-up was explicit and unhedged. Management didn't bury the spend increase in tax-rate optics. The press release names "acceleration of povetacicept programs and increased investment in sales and marketing initiatives for JOURNAVX" as the drivers of the ~$100M increase to the non-GAAP combined opex guide. This is more transparent than the prior reiterated guide and signals confidence the spend will produce visible returns.

Recurring themes management leaned on this quarter:

Portfolio diversification beyond CF into pain and renal diseasesUnprecedented clinical efficacy in CF across age groups and mutationsGenavix adoption accelerating independent of payer coverage completionRenal franchise emerging as transformational fourth pillarPOVI regulatory momentum and clinical differentiation versus competitive classInfrastructure and commercialization readiness advancing across multiple launches

Risks management surfaced:

Tariffs and geopolitical supply chain impacts (noted as immaterial in 2025 but subject to change)Competitive intensity in IgA nephropathy indicationManufacturing analysis delay in Zamylocell Type 1 diabetes (temporarily postponed dosing completion)Payer coverage gaps requiring patient support program extension into 2026Third PBM contracting for Genavix still in active negotiations

Answers to last quarter's watch list

Journavx revenue scaling above $50M in Q3 — Missed by a wide margin. Q3 revenue came in at $20M against 300,000+ YTD prescriptions and 170M+ covered lives. The volume and access are tracking management's narrative, but gross-to-net conversion remains the binding constraint — the patient support program that management flagged in Q2 is still suppressing reported revenue. The "multi-billion dollar franchise" framing now depends entirely on when patient support wind-down lets net pricing reset higher. Status: Resolved negatively

Alyftrek-to-Trikafta transition pace and combined CF growth — Alyftrek hit $247M (up from $157M in Q2), Trikafta/Kaftrio at $2.65B grew only 2.6% YoY. Combined CF revenue of ~$2.90B is up roughly 5–6% YoY, which is below Q2's double-digit pace as conversion accelerates. Pacing is consistent with management's framing — the transition is happening faster than the CF base is eroding, but the optics on the headline Trikafta line are now visibly decelerating. Status: Continue monitoring

Casgevy infusion cadence sustaining sequential growth — 39 cumulative infusions vs. 29 in Q2 = roughly 10 incremental infusions in Q3, marginally below Q2's 16-infusion pace. However, cell collections accelerated to 165 cumulative — a deep enough pipeline that infusions should rebuild. Management publicly underwrote >$100M Casgevy revenue for FY2025 and "significant growth in 2026." Status: Continue monitoring

DPN Phase III second-trial initiation timing — Not disclosed in the press release. The company didn't call out a start date for the second DPN trial. Status: Not resolved

VX828 (next-gen CFTR) pipeline disclosures — Not disclosed in the press release. No Phase I dosing milestones surfaced. Status: Not resolved

Gross-to-net dynamics on Journavx — Effectively answered, and the answer is negative. $20M revenue on 300,000+ YTD scripts implies sub-$70 net per Rx — well below list — confirming the patient support program is still absorbing most of the gross-to-net gap. Management did not disclose a wind-down timeline. Status: Resolved negatively

What to watch into next quarter

POVI BLA submission confirmation — management committed to begin submission "before the end of this year"; watch the Q4 press release or 8-K for explicit confirmation, since the submission anchors the accelerated approval timeline

Journavx net revenue per Rx — Q3 implied roughly $65–70 per Rx ($20M / 300,000+ YTD); watch whether Q4 net per Rx moves into the $100+ range as patient support program steps down, which is the actual unlock for the "multi-billion dollar" framing

Combined CF franchise growth rate — Trikafta/Kaftrio + Alyftrek combined growth decelerated from ~12% in Q2 to ~5–6% in Q3; watch whether combined CF holds at mid-single-digits or drops to flat as the Alyftrek transition matures

Casgevy quarterly infusion pace — 10 incremental infusions in Q3 vs. 16 in Q2; watch whether Q4 reaccelerates above 15 infusions, the pace needed to deliver on the >$100M FY2025 commitment and underwrite 2026 growth

FY2026 opex guide directionality — the ~$100M Q3 non-GAAP step-up was framed as accelerating investment; watch the Q4 print for whether SG&A growth carries into the FY2026 guide, which would confirm Vertex is building a permanent multi-franchise cost structure rather than a one-year launch spike

Povetacicept second-indication trial enrollment pace — primary membranous nephropathy pivotal just initiated; watch enrollment cadence relative to the IgAN benchmark (600 patients in 15 months) as a tell for unmet-need conviction across the renal franchise

Sources

Vertex Pharmaceuticals Q3 2025 press release (SEC EDGAR Ex-99.1): https://www.sec.gov/Archives/edgar/data/875320/000087532025000230/ex-991_q32025.htm

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.